CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The San Antonio Breast Cancer Symposium (SABCS) is an annual event cosponsored by the AACR and UT Health San Antonio’s Mays Cancer Center. The meeting hosts about 10,000 clinicians and scientists from all over the world and is the largest and most prestigious scientific gathering on breast cancer research. This international scientific symposium allows for the important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of breast cancer.
American Society of Hematology Annual Meeting and Exposition is the world’s most comprehensive hematology event of the year. ASH is a professional society concerned with the causes and treatments of blood disorders.
The Roster Interface Program & Participants List Environment (Ripple) is a single electronic system which permits:
Canadian Cancer Statistics provides comprehensive surveillance statistics on cancer in Canada. The full publication is produced every second year and includes detailed statistics on incidence, mortality and survival by sex, age group, geographic region and time period for 20+ cancer types.
